Share Price and Basic Stock Data
Last Updated: November 26, 2025, 4:40 pm
| PEG Ratio | 0.64 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Biofil Chemicals & Pharmaceuticals Ltd operates within the pharmaceuticals sector, reflecting a market capitalization of ₹63.1 Cr and a share price of ₹39.2. The company’s revenue trajectory has shown volatility over recent quarters. For instance, sales recorded in March 2023 stood at ₹30.04 Cr, increasing to ₹40.04 Cr in March 2024 before declining to ₹33.40 Cr in March 2025. The trailing twelve months (TTM) revenue rose to ₹42.52 Cr, indicating a recovery from previous fluctuations. Quarterly sales trends also reveal significant variability, with a peak of ₹17.37 Cr in September 2023 and a low of ₹1.49 Cr in December 2022. This inconsistency in revenue generation may be attributed to market dynamics and operational challenges within the pharmaceutical industry, which typically sees higher stability and growth compared to Biofil’s performance. Overall, while the company has managed to achieve substantial revenue figures at certain points, the erratic nature of its sales raises concerns about long-term sustainability.
Profitability and Efficiency Metrics
Biofil’s profitability metrics have exhibited a mixed performance. The operating profit margin (OPM) for March 2025 stood at 2.54%, a decline from 5.94% in March 2022, reflecting challenges in maintaining operational efficiency. The net profit margin also decreased from 3.12% in March 2022 to 1.66% in March 2025, indicating pressure on profitability. However, the interest coverage ratio (ICR) remains robust at 31.24x, suggesting that the company can comfortably meet its interest obligations despite lower profitability margins. The return on equity (ROE) is reported at 3.03%, which is below the typical sector average, indicating less efficient use of shareholders’ equity. Furthermore, the cash conversion cycle (CCC) is recorded at 91.63 days, signaling potential issues in managing working capital effectively. Collectively, these metrics highlight the need for Biofil to enhance its operational efficiency and profitability to align more closely with industry standards.
Balance Sheet Strength and Financial Ratios
Biofil Chemicals & Pharmaceuticals Ltd presents a relatively stable balance sheet, with total borrowings recorded at ₹0.47 Cr, indicating a low debt-to-equity ratio of 0.02. This low leverage suggests a conservative approach to financing, which can be advantageous in uncertain market conditions. The company’s reserves have improved significantly, rising from ₹1.03 Cr in March 2023 to ₹2.51 Cr in March 2025, reflecting a gradual strengthening of the financial position. However, the price-to-book value (P/BV) ratio stands at 3.56x, suggesting that the stock may be trading at a premium compared to its book value, which could indicate overvaluation. Additionally, the return on capital employed (ROCE) is reported at 4.12%, below expected sector levels, highlighting inefficiencies in using capital. Overall, while Biofil maintains a low debt level, its profitability and capital utilization metrics warrant further scrutiny.
Shareholding Pattern and Investor Confidence
The shareholding structure of Biofil Chemicals & Pharmaceuticals Ltd reveals a significant public ownership of 53.12%, while promoters hold 46.79%. The absence of foreign institutional investors (FIIs) suggests a lack of confidence from international investors, which could be concerning for future growth prospects. Domestic institutional investors (DIIs) hold a minimal 0.08%, indicating limited institutional interest in the company. This could reflect skepticism regarding the company’s operational performance and growth potential. The number of shareholders has also declined from 28,378 in December 2022 to 25,196 by March 2025, further indicating waning interest among retail investors. Such trends may affect the stock’s liquidity and market perception, potentially leading to increased volatility. A lack of institutional backing could hinder the company’s ability to raise capital for expansion or innovation, which is critical in the competitive pharmaceutical landscape.
Outlook, Risks, and Final Insight
Looking ahead, Biofil Chemicals & Pharmaceuticals Ltd faces a mixed outlook, characterized by both opportunities and risks. The company’s low leverage and improving reserves position it favorably to navigate financial challenges. However, the volatility in revenue and declining profitability margins raise concerns about its operational effectiveness. The pharmaceutical industry is typically characterized by stable growth; thus, Biofil must enhance its operational efficiencies to align with sector norms. Potential risks include continued revenue volatility, low institutional interest, and challenges in maintaining profit margins. On the other hand, if the company can stabilize its revenue streams and improve operational efficiencies, it may unlock significant potential for growth. The management’s ability to address these challenges will be crucial in determining Biofil’s future trajectory and its appeal to investors in the competitive pharmaceutical market.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Biofil Chemicals & Pharmaceuticals Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 162 Cr. | 129 | 247/84.3 | 35.9 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,538 Cr. | 417 | 479/192 | 94.0 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.9 Cr. | 47.0 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 41.5 Cr. | 28.3 | 29.1/17.0 | 98.8 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,356.00 Cr | 1,182.92 | 52.67 | 202.40 | 0.35% | 16.24% | 14.95% | 6.10 |
All Competitor Stocks of Biofil Chemicals & Pharmaceuticals Ltd
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 12.31 | 2.62 | 1.49 | 13.62 | 2.43 | 17.37 | 5.03 | 15.20 | 8.44 | 2.41 | 14.20 | 8.35 | 6.43 |
| Expenses | 11.94 | 2.46 | 1.26 | 13.21 | 2.01 | 17.13 | 4.84 | 15.24 | 8.13 | 2.29 | 13.89 | 8.24 | 6.42 |
| Operating Profit | 0.37 | 0.16 | 0.23 | 0.41 | 0.42 | 0.24 | 0.19 | -0.04 | 0.31 | 0.12 | 0.31 | 0.11 | 0.01 |
| OPM % | 3.01% | 6.11% | 15.44% | 3.01% | 17.28% | 1.38% | 3.78% | -0.26% | 3.67% | 4.98% | 2.18% | 1.32% | 0.16% |
| Other Income | 0.02 | 0.02 | 0.02 | 0.03 | 0.02 | 0.03 | 0.03 | 0.41 | 0.03 | 0.02 | 0.02 | 0.24 | 2.83 |
| Interest | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Depreciation | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | 0.08 | 0.10 | 0.10 | 0.10 | 0.08 | 0.07 |
| Profit before tax | 0.27 | 0.06 | 0.13 | 0.32 | 0.32 | 0.15 | 0.11 | 0.27 | 0.23 | 0.03 | 0.22 | 0.26 | 2.76 |
| Tax % | 25.93% | 33.33% | 23.08% | 34.38% | 25.00% | 20.00% | 18.18% | 11.11% | 26.09% | 33.33% | 27.27% | 23.08% | 12.68% |
| Net Profit | 0.21 | 0.05 | 0.10 | 0.21 | 0.24 | 0.12 | 0.09 | 0.25 | 0.17 | 0.02 | 0.16 | 0.20 | 2.41 |
| EPS in Rs | 0.13 | 0.03 | 0.06 | 0.13 | 0.15 | 0.07 | 0.06 | 0.15 | 0.10 | 0.01 | 0.10 | 0.12 | 1.48 |
Last Updated: August 20, 2025, 12:45 pm
Below is a detailed analysis of the quarterly data for Biofil Chemicals & Pharmaceuticals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 6.43 Cr.. The value appears to be declining and may need further review. It has decreased from 8.35 Cr. (Mar 2025) to 6.43 Cr., marking a decrease of 1.92 Cr..
- For Expenses, as of Jun 2025, the value is 6.42 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 8.24 Cr. (Mar 2025) to 6.42 Cr., marking a decrease of 1.82 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.01 Cr.. The value appears to be declining and may need further review. It has decreased from 0.11 Cr. (Mar 2025) to 0.01 Cr., marking a decrease of 0.10 Cr..
- For OPM %, as of Jun 2025, the value is 0.16%. The value appears to be declining and may need further review. It has decreased from 1.32% (Mar 2025) to 0.16%, marking a decrease of 1.16%.
- For Other Income, as of Jun 2025, the value is 2.83 Cr.. The value appears strong and on an upward trend. It has increased from 0.24 Cr. (Mar 2025) to 2.83 Cr., marking an increase of 2.59 Cr..
- For Interest, as of Jun 2025, the value is 0.01 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.01 Cr..
- For Depreciation, as of Jun 2025, the value is 0.07 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.08 Cr. (Mar 2025) to 0.07 Cr., marking a decrease of 0.01 Cr..
- For Profit before tax, as of Jun 2025, the value is 2.76 Cr.. The value appears strong and on an upward trend. It has increased from 0.26 Cr. (Mar 2025) to 2.76 Cr., marking an increase of 2.50 Cr..
- For Tax %, as of Jun 2025, the value is 12.68%. The value appears to be improving (decreasing) as expected. It has decreased from 23.08% (Mar 2025) to 12.68%, marking a decrease of 10.40%.
- For Net Profit, as of Jun 2025, the value is 2.41 Cr.. The value appears strong and on an upward trend. It has increased from 0.20 Cr. (Mar 2025) to 2.41 Cr., marking an increase of 2.21 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.48. The value appears strong and on an upward trend. It has increased from 0.12 (Mar 2025) to 1.48, marking an increase of 1.36.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 5:38 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 7.17 | 5.86 | 13.17 | 13.45 | 12.36 | 23.13 | 29.69 | 35.75 | 22.38 | 30.04 | 40.04 | 33.40 | 42.52 |
| Expenses | 6.21 | 5.12 | 12.30 | 10.84 | 11.43 | 22.11 | 27.87 | 34.15 | 21.05 | 28.88 | 39.23 | 32.55 | 41.97 |
| Operating Profit | 0.96 | 0.74 | 0.87 | 2.61 | 0.93 | 1.02 | 1.82 | 1.60 | 1.33 | 1.16 | 0.81 | 0.85 | 0.55 |
| OPM % | 13.39% | 12.63% | 6.61% | 19.41% | 7.52% | 4.41% | 6.13% | 4.48% | 5.94% | 3.86% | 2.02% | 2.54% | 1.29% |
| Other Income | 0.06 | 0.46 | 0.53 | 0.14 | 0.10 | 0.10 | 0.17 | 0.80 | 0.15 | 0.10 | 0.49 | 0.31 | 3.15 |
| Interest | 0.15 | 0.21 | 0.15 | 0.16 | 0.15 | 0.16 | 0.12 | 0.07 | 0.04 | 0.04 | 0.04 | 0.04 | 0.03 |
| Depreciation | 0.22 | 0.25 | 0.26 | 0.28 | 0.30 | 0.37 | 0.41 | 0.41 | 0.43 | 0.43 | 0.40 | 0.38 | 0.32 |
| Profit before tax | 0.65 | 0.74 | 0.99 | 2.31 | 0.58 | 0.59 | 1.46 | 1.92 | 1.01 | 0.79 | 0.86 | 0.74 | 3.35 |
| Tax % | 20.00% | 20.27% | 20.20% | 22.51% | 20.69% | 20.34% | 17.81% | 34.90% | 31.68% | 29.11% | 17.44% | 24.32% | |
| Net Profit | 0.52 | 0.59 | 0.78 | 1.79 | 0.47 | 0.48 | 1.21 | 1.24 | 0.70 | 0.56 | 0.71 | 0.56 | 2.85 |
| EPS in Rs | 0.32 | 0.36 | 0.48 | 1.10 | 0.29 | 0.29 | 0.74 | 0.76 | 0.43 | 0.34 | 0.44 | 0.34 | 1.75 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 13.46% | 32.20% | 129.49% | -73.74% | 2.13% | 152.08% | 2.48% | -43.55% | -20.00% | 26.79% | -21.13% |
| Change in YoY Net Profit Growth (%) | 0.00% | 18.74% | 97.28% | -203.23% | 75.87% | 149.96% | -149.60% | -46.03% | 23.55% | 46.79% | -47.91% |
Biofil Chemicals & Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 2% |
| 3 Years: | 14% |
| TTM: | -32% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | -14% |
| 3 Years: | -7% |
| TTM: | 343% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | 5% |
| 3 Years: | -7% |
| 1 Year: | -32% |
| Return on Equity | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 4% |
| 3 Years: | 3% |
| Last Year: | 3% |
Last Updated: September 5, 2025, 1:00 am
Balance Sheet
Last Updated: November 9, 2025, 1:46 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 |
| Reserves | -8.41 | -7.86 | -5.37 | -3.58 | -3.11 | -2.62 | -1.39 | -0.14 | 0.56 | 1.03 | 1.93 | 2.51 |
| Borrowings | 2.87 | 2.98 | 1.37 | 1.43 | 1.56 | 1.64 | 1.19 | 0.43 | 0.46 | 0.52 | 0.44 | 0.47 |
| Other Liabilities | 3.87 | 2.36 | 11.87 | 7.72 | 9.44 | 8.93 | 26.30 | 16.68 | 1.44 | 13.58 | 28.44 | 31.70 |
| Total Liabilities | 14.60 | 13.75 | 24.14 | 21.84 | 24.16 | 24.22 | 42.37 | 33.24 | 18.73 | 31.40 | 47.08 | 50.95 |
| Fixed Assets | 9.17 | 9.06 | 8.98 | 9.16 | 9.25 | 10.29 | 10.09 | 9.78 | 9.42 | 9.00 | 8.62 | 8.34 |
| CWIP | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Investments | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Other Assets | 5.43 | 4.69 | 15.16 | 12.68 | 14.91 | 13.93 | 32.28 | 23.46 | 9.31 | 22.40 | 38.46 | 42.61 |
| Total Assets | 14.60 | 13.75 | 24.14 | 21.84 | 24.16 | 24.22 | 42.37 | 33.24 | 18.73 | 31.40 | 47.08 | 50.95 |
Below is a detailed analysis of the balance sheet data for Biofil Chemicals & Pharmaceuticals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 16.27 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 16.27 Cr..
- For Reserves, as of Mar 2025, the value is 2.51 Cr.. The value appears strong and on an upward trend. It has increased from 1.93 Cr. (Mar 2024) to 2.51 Cr., marking an increase of 0.58 Cr..
- For Borrowings, as of Mar 2025, the value is 0.47 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 0.44 Cr. (Mar 2024) to 0.47 Cr., marking an increase of 0.03 Cr..
- For Other Liabilities, as of Mar 2025, the value is 31.70 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 28.44 Cr. (Mar 2024) to 31.70 Cr., marking an increase of 3.26 Cr..
- For Total Liabilities, as of Mar 2025, the value is 50.95 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 47.08 Cr. (Mar 2024) to 50.95 Cr., marking an increase of 3.87 Cr..
- For Fixed Assets, as of Mar 2025, the value is 8.34 Cr.. The value appears to be declining and may need further review. It has decreased from 8.62 Cr. (Mar 2024) to 8.34 Cr., marking a decrease of 0.28 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 42.61 Cr.. The value appears strong and on an upward trend. It has increased from 38.46 Cr. (Mar 2024) to 42.61 Cr., marking an increase of 4.15 Cr..
- For Total Assets, as of Mar 2025, the value is 50.95 Cr.. The value appears strong and on an upward trend. It has increased from 47.08 Cr. (Mar 2024) to 50.95 Cr., marking an increase of 3.87 Cr..
Notably, the Reserves (2.51 Cr.) exceed the Borrowings (0.47 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -1.91 | -2.24 | -0.50 | 1.18 | -0.63 | -0.62 | 0.63 | 1.17 | 0.87 | 0.64 | 0.37 | 0.38 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 208.72 | 227.35 | 387.45 | 311.00 | 383.31 | 189.84 | 365.25 | 175.81 | 116.94 | 249.08 | 301.10 | 418.77 |
| Inventory Days | 20.53 | 15.99 | 3.46 | 7.29 | 38.11 | 21.73 | 24.37 | 48.85 | 24.20 | 16.11 | 24.81 | 39.52 |
| Days Payable | 276.79 | 198.49 | 400.98 | 304.52 | 341.46 | 156.66 | 373.80 | 178.39 | 11.25 | 168.39 | 268.08 | 366.66 |
| Cash Conversion Cycle | -47.54 | 44.85 | -10.07 | 13.76 | 79.95 | 54.90 | 15.82 | 46.27 | 129.88 | 96.80 | 57.83 | 91.63 |
| Working Capital Days | -75.85 | -47.96 | 48.50 | 87.65 | 104.83 | 50.81 | 55.69 | 64.12 | 125.25 | 104.25 | 69.37 | 114.09 |
| ROCE % | 7.66% | 8.59% | 9.64% | 18.72% | 5.06% | 5.00% | 10.08% | 12.20% | 6.20% | 4.73% | 4.94% | 4.12% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.34 | 0.44 | 0.34 | 0.44 | 0.76 |
| Diluted EPS (Rs.) | 0.34 | 0.44 | 0.34 | 0.44 | 0.76 |
| Cash EPS (Rs.) | 0.57 | 0.68 | 0.60 | 0.69 | 1.01 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 11.54 | 11.19 | 10.63 | 10.35 | 9.91 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 11.54 | 11.19 | 10.63 | 10.35 | 9.91 |
| Revenue From Operations / Share (Rs.) | 20.52 | 24.60 | 18.46 | 13.75 | 21.97 |
| PBDIT / Share (Rs.) | 0.70 | 0.80 | 0.77 | 0.91 | 1.47 |
| PBIT / Share (Rs.) | 0.47 | 0.55 | 0.51 | 0.64 | 1.22 |
| PBT / Share (Rs.) | 0.45 | 0.53 | 0.48 | 0.62 | 1.18 |
| Net Profit / Share (Rs.) | 0.34 | 0.43 | 0.34 | 0.42 | 0.76 |
| PBDIT Margin (%) | 3.45 | 3.26 | 4.21 | 6.62 | 6.71 |
| PBIT Margin (%) | 2.31 | 2.26 | 2.78 | 4.71 | 5.55 |
| PBT Margin (%) | 2.20 | 2.16 | 2.64 | 4.53 | 5.36 |
| Net Profit Margin (%) | 1.66 | 1.77 | 1.86 | 3.12 | 3.47 |
| Return on Networth / Equity (%) | 2.96 | 3.89 | 3.23 | 4.14 | 7.69 |
| Return on Capital Employeed (%) | 4.04 | 4.88 | 4.72 | 6.12 | 12.05 |
| Return On Assets (%) | 1.09 | 1.50 | 1.78 | 3.72 | 3.73 |
| Total Debt / Equity (X) | 0.02 | 0.02 | 0.03 | 0.02 | 0.02 |
| Asset Turnover Ratio (%) | 0.68 | 1.02 | 1.20 | 0.86 | 0.94 |
| Current Ratio (X) | 1.34 | 1.35 | 1.63 | 6.23 | 1.40 |
| Quick Ratio (X) | 1.23 | 1.26 | 1.54 | 5.37 | 1.14 |
| Inventory Turnover Ratio (X) | 11.34 | 2.79 | 3.13 | 0.80 | 2.27 |
| Interest Coverage Ratio (X) | 31.24 | 31.47 | 29.76 | 36.53 | 35.23 |
| Interest Coverage Ratio (Post Tax) (X) | 16.11 | 18.09 | 14.19 | 18.20 | 19.23 |
| Enterprise Value (Cr.) | 67.15 | 96.38 | 67.93 | 94.38 | 106.83 |
| EV / Net Operating Revenue (X) | 2.01 | 2.41 | 2.26 | 4.22 | 2.99 |
| EV / EBITDA (X) | 58.26 | 73.79 | 53.71 | 63.64 | 44.53 |
| MarketCap / Net Operating Revenue (X) | 2.00 | 2.45 | 2.25 | 4.20 | 2.99 |
| Price / BV (X) | 3.56 | 5.40 | 3.90 | 5.59 | 6.62 |
| Price / Net Operating Revenue (X) | 2.00 | 2.45 | 2.25 | 4.20 | 2.99 |
| EarningsYield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
After reviewing the key financial ratios for Biofil Chemicals & Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.34. This value is below the healthy minimum of 5. It has decreased from 0.44 (Mar 24) to 0.34, marking a decrease of 0.10.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.34. This value is below the healthy minimum of 5. It has decreased from 0.44 (Mar 24) to 0.34, marking a decrease of 0.10.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.57. This value is below the healthy minimum of 3. It has decreased from 0.68 (Mar 24) to 0.57, marking a decrease of 0.11.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 11.54. It has increased from 11.19 (Mar 24) to 11.54, marking an increase of 0.35.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 11.54. It has increased from 11.19 (Mar 24) to 11.54, marking an increase of 0.35.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 20.52. It has decreased from 24.60 (Mar 24) to 20.52, marking a decrease of 4.08.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.70. This value is below the healthy minimum of 2. It has decreased from 0.80 (Mar 24) to 0.70, marking a decrease of 0.10.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.47. This value is within the healthy range. It has decreased from 0.55 (Mar 24) to 0.47, marking a decrease of 0.08.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.45. This value is within the healthy range. It has decreased from 0.53 (Mar 24) to 0.45, marking a decrease of 0.08.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.34. This value is below the healthy minimum of 2. It has decreased from 0.43 (Mar 24) to 0.34, marking a decrease of 0.09.
- For PBDIT Margin (%), as of Mar 25, the value is 3.45. This value is below the healthy minimum of 10. It has increased from 3.26 (Mar 24) to 3.45, marking an increase of 0.19.
- For PBIT Margin (%), as of Mar 25, the value is 2.31. This value is below the healthy minimum of 10. It has increased from 2.26 (Mar 24) to 2.31, marking an increase of 0.05.
- For PBT Margin (%), as of Mar 25, the value is 2.20. This value is below the healthy minimum of 10. It has increased from 2.16 (Mar 24) to 2.20, marking an increase of 0.04.
- For Net Profit Margin (%), as of Mar 25, the value is 1.66. This value is below the healthy minimum of 5. It has decreased from 1.77 (Mar 24) to 1.66, marking a decrease of 0.11.
- For Return on Networth / Equity (%), as of Mar 25, the value is 2.96. This value is below the healthy minimum of 15. It has decreased from 3.89 (Mar 24) to 2.96, marking a decrease of 0.93.
- For Return on Capital Employeed (%), as of Mar 25, the value is 4.04. This value is below the healthy minimum of 10. It has decreased from 4.88 (Mar 24) to 4.04, marking a decrease of 0.84.
- For Return On Assets (%), as of Mar 25, the value is 1.09. This value is below the healthy minimum of 5. It has decreased from 1.50 (Mar 24) to 1.09, marking a decrease of 0.41.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.02. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.02.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.68. It has decreased from 1.02 (Mar 24) to 0.68, marking a decrease of 0.34.
- For Current Ratio (X), as of Mar 25, the value is 1.34. This value is below the healthy minimum of 1.5. It has decreased from 1.35 (Mar 24) to 1.34, marking a decrease of 0.01.
- For Quick Ratio (X), as of Mar 25, the value is 1.23. This value is within the healthy range. It has decreased from 1.26 (Mar 24) to 1.23, marking a decrease of 0.03.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 11.34. This value exceeds the healthy maximum of 8. It has increased from 2.79 (Mar 24) to 11.34, marking an increase of 8.55.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 31.24. This value is within the healthy range. It has decreased from 31.47 (Mar 24) to 31.24, marking a decrease of 0.23.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 16.11. This value is within the healthy range. It has decreased from 18.09 (Mar 24) to 16.11, marking a decrease of 1.98.
- For Enterprise Value (Cr.), as of Mar 25, the value is 67.15. It has decreased from 96.38 (Mar 24) to 67.15, marking a decrease of 29.23.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.01. This value is within the healthy range. It has decreased from 2.41 (Mar 24) to 2.01, marking a decrease of 0.40.
- For EV / EBITDA (X), as of Mar 25, the value is 58.26. This value exceeds the healthy maximum of 15. It has decreased from 73.79 (Mar 24) to 58.26, marking a decrease of 15.53.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.00. This value is within the healthy range. It has decreased from 2.45 (Mar 24) to 2.00, marking a decrease of 0.45.
- For Price / BV (X), as of Mar 25, the value is 3.56. This value exceeds the healthy maximum of 3. It has decreased from 5.40 (Mar 24) to 3.56, marking a decrease of 1.84.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.00. This value is within the healthy range. It has decreased from 2.45 (Mar 24) to 2.00, marking a decrease of 0.45.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Biofil Chemicals & Pharmaceuticals Ltd:
- Net Profit Margin: 1.66%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 4.04% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 2.96% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 16.11
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.23
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 20.7 (Industry average Stock P/E: 52.67)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.02
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 1.66%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | B/12-B Industrial Estate, Pologround, Indore Madhya Pradesh 452015 | bcplcompliance@gmail.com http://www.biofilgroup.net |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Ketan Shah | Chairman & Managing Director |
| Mr. Smitesh Shah | Non Exe.Non Ind.Director |
| Mr. Meet Shah | Non Exe.Non Ind.Director |
| Mr. Satish Beohar | Ind. Non-Executive Director |
| Mr. Ashok Kumar Ramawat | Ind. Non-Executive Director |
| Mrs. Gayatri Padiyar | Ind. Non-Executive Woman Director |
FAQ
What is the intrinsic value of Biofil Chemicals & Pharmaceuticals Ltd?
Biofil Chemicals & Pharmaceuticals Ltd's intrinsic value (as of 26 November 2025) is 6.70 which is 81.84% lower the current market price of 36.90, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 58.9 Cr. market cap, FY2025-2026 high/low of 72.0/35.5, reserves of ₹2.51 Cr, and liabilities of 50.95 Cr.
What is the Market Cap of Biofil Chemicals & Pharmaceuticals Ltd?
The Market Cap of Biofil Chemicals & Pharmaceuticals Ltd is 58.9 Cr..
What is the current Stock Price of Biofil Chemicals & Pharmaceuticals Ltd as on 26 November 2025?
The current stock price of Biofil Chemicals & Pharmaceuticals Ltd as on 26 November 2025 is 36.9.
What is the High / Low of Biofil Chemicals & Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Biofil Chemicals & Pharmaceuticals Ltd stocks is 72.0/35.5.
What is the Stock P/E of Biofil Chemicals & Pharmaceuticals Ltd?
The Stock P/E of Biofil Chemicals & Pharmaceuticals Ltd is 20.7.
What is the Book Value of Biofil Chemicals & Pharmaceuticals Ltd?
The Book Value of Biofil Chemicals & Pharmaceuticals Ltd is 13.1.
What is the Dividend Yield of Biofil Chemicals & Pharmaceuticals Ltd?
The Dividend Yield of Biofil Chemicals & Pharmaceuticals Ltd is 0.00 %.
What is the ROCE of Biofil Chemicals & Pharmaceuticals Ltd?
The ROCE of Biofil Chemicals & Pharmaceuticals Ltd is 4.12 %.
What is the ROE of Biofil Chemicals & Pharmaceuticals Ltd?
The ROE of Biofil Chemicals & Pharmaceuticals Ltd is 3.03 %.
What is the Face Value of Biofil Chemicals & Pharmaceuticals Ltd?
The Face Value of Biofil Chemicals & Pharmaceuticals Ltd is 10.0.